切换至 "中华医学电子期刊资源库"

中华产科急救电子杂志 ›› 2017, Vol. 06 ›› Issue (02) : 92 -97. doi: 10.3877/cma.j.issn.2095-3259.2017.02.007

所属专题: 文献

专家论坛

妊娠期重症肝炎的防治
韩国荣1,(), 许传露2   
  1. 1. 210003 南京市,东南大学附属第二医院 南京市第二医院妇产科
    2. 200400 上海,同济大学附属上海市第一妇婴保健院妇产科
  • 收稿日期:2017-01-30 出版日期:2017-05-18
  • 通信作者: 韩国荣
  • 基金资助:
    国家自然基金面上项目(81370583); 江苏省临床重大专项(BL2014006)

Prevention and treatment of severe hepatitis in pregnancy

Guorong Han1(), Chuanlu Xu2   

  • Received:2017-01-30 Published:2017-05-18
  • Corresponding author: Guorong Han
引用本文:

韩国荣, 许传露. 妊娠期重症肝炎的防治[J]. 中华产科急救电子杂志, 2017, 06(02): 92-97.

Guorong Han, Chuanlu Xu. Prevention and treatment of severe hepatitis in pregnancy[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2017, 06(02): 92-97.

重症肝炎是指肝细胞在短期内大量坏死或严重变性所致的肝衰竭。该病特点为发展迅速、病情严重、并发症多、病死率高。妊娠合并重症肝炎的治疗强调早期识别、及时转诊、严密监测、孕期抗病毒、多学科协作等综合治疗,同时积极防治并发症,适时终止妊娠,以降低孕产妇与围产儿的病死率。

Severe hepatitis refers that lots of liver cells occur necrosis or serious degeneration in a short term, which cause liver failure. The characteristics of severe hepatitis are rapid aggressive clinical course, severe condition, many complications and high fatality. To reduce maternal and perinatal mortality, the treatments of sever hepatitis not only emphasize on early recognition, timely referral, close monitoring, antiviral treatment and interdisciplinary cooperation, but also include prevention the complications actively and terminating pregnancy timely.

表1 妊娠合并重症肝炎的鉴别诊断[9]
[1]
Lefkowitch JH. The pathology of acute liver failure[J]. Adv Anat Pathol, 2016, 23(3):144-158.
[2]
Li XM, Ma L, Yang YB, et al. Clinical characteristics of fulminant hepatitis in pregnancy[J]. World J Gastroenterol, 2005, 11(29):4600-4603.
[3]
Jin H, Zhao Y, Zhang X, et al. Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis[J]. Epidemiol Infect, 2016, 144(10):2098-2106.
[4]
Khuroo MS, Khuroo MS, Khuroo NS. Discovery, global impact, control and cure[J]. World J Gastroenterol, 2016, 22(31):7030-7045.
[5]
Licata A, Ingrassia D, Serruto A, et al. Clinical course and management of acute and chronic viral hepatitis during pregnancy[J]. J Viral Hepat, 2015, 22(6):515-523.
[6]
Halliday J, Lokan J, Angus PW, et al. A case of fulminant hepatic failure in pregnancy[J]. Hepatology, 2010, 51(1):341-342.
[7]
李小毛. 妊娠合并重型肝炎的治疗现状及进展[J]. 新医学,2005, 36(2):65-67.
[8]
马洁,刘建. 妊娠合并重症肝炎的诊治进展[J]. 医学信息,2014, 27(4):495-496.
[9]
郝秀兰,侯红瑛. 关于妊娠合并重症肝炎[J/CD]. 中华产科急救电子杂志,2012, 1(1):14-16.
[10]
尹玉竹,周瑾. 妊娠合并肝衰竭的产科处理[J/CD]. 中华产科急救电子杂志,2014, 3(3):172-175.
[11]
黄琳琳,刘建. 妊娠合并重症肝炎治疗进展[J]. 中外医疗,2015, (11):194-196.
[12]
McCormick PA, Donnelly C. Management of hepatorenal syndrome[J]. Pharmacol Ther, 2008, 119(1):1-6.
[13]
Li M, Sun J, Li J, et al. Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver[J]. Exp Ther Med, 2016, 12(6):3873-3876.
[14]
Komura T, Taniguchi T, Sakai Y, et al. Efficacy of continuous plasma diafiltration therapy in critical patients with acute liver failure[J]. J Gastroenterol Hepatol, 2014, 29(4):782-786.
[15]
Wu DB, Chen EQ, Bai L, et al. Propylthiouracil-induced liver failure and artificial liver support systems: a case report and review of the literature[J]. Ther Clin Risk Manag, 2017, 13:65-68.
[16]
Mendizabal M, Rowe C, Piñero F, et al. Successful orthotopic liver transplantation and delayed delivery of a healthy newborn in a woman with fulminant hepatic failure during the second trimester of pregnancy[J]. Ann Hepatol, 2014, 13(2):288-292.
[17]
唐晖,傅斌生,易慧敏,等. 肝移植治疗妊娠期合并急性肝衰竭2例并文献复习[J]. 器官移植,2015, 6(6):388-391.
[18]
Mendizabal M, Silva MO. Liver transplantation in acute liver failure: A challenging scenario[J]. World J Gastroenterol, 2016, 22(4):1523-1531.
[19]
Fukumitsu K, Yagi H, Soto-Gutierrez A.Bioengineering in organ transplantation: targeting the liver[J]. Transplant Proc, 2011,43(6):2137-2138.
[20]
Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy[J]. Semin Liver Dis, 2013, 33(2):138-146.
[21]
Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2012, 10(5):520-526.
[22]
Han GR, Jiang HX, Wang CM, et al. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy[J]. J Viral Hepat, 2017, 24(2):514-521.
[23]
Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55(6):1215-1221.
[24]
Han GR, Jiang HX, Yue X, et al. Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Viral Hepat, 2015, 22(9):754-762.
[25]
Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study[J]. J Viral Hepat, 2009, 16(2):94-103.
[26]
Tran TT. Management of hepatitis B in pregnancy: weighing the options[J]. Cleve Clin J Med, 2009, 76(Suppl 3):S25-S29.
[27]
Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis b transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374(24):2324-2334.
[28]
Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management[J]. J Hepatol, 2014, 61(6):1407-1417.
[29]
Han GR, Xu CL, Zhao W, et al. Management of chronic hepatitis B in pregnancy[J]. World J Gastroenterol, 2012, 18(33):4517-4521.
[30]
韩国荣,丁祎. 慢性乙型肝炎育龄妇女及孕妇的抗病毒治疗指征与时机的选择[J]. 中华肝脏病杂志,2015, 23(11):806-809.
[31]
Chen H, Yuan L, Tan J, et al. Severe liver disease in pregnancy[J]. Int J Gynaecol Obstet, 2008, 101(3):277-280.
[32]
李小毛. 晚期妊娠合并重型肝炎产科处理的若干问题[J].广东医学,2007, 28(5):683-684.
[33]
Deng L, Li X, Shi Z, et al. Maternal and perinatal outcome in cases of fulminant viral hepatitis in late pregnancy[J]. Int J Gynaecol Obstet, 2012, 119(2):145-148.
[34]
Labrique AB, Sikder SS, Krain LJ, et al. Hepatitis E, a vaccine preventable cause of maternal deaths[J]. Emerg Infect Dis, 2012, 18(9):1401-1404.
[35]
Kumar M, Singh T, Sinha S. Chronic hepatitis B virus infection and pregnancy[J]. J Clin Exp Hepatol, 2012, 2(4):366-381.
[1] 高建松, 陈晓晓, 冯婷, 包剑锋, 魏淑芳, 潘林. 基于超声瞬时弹性成像的多参数决策树模型评估慢性乙型肝炎患者肝纤维化等级[J]. 中华医学超声杂志(电子版), 2023, 20(09): 923-929.
[2] 葛飞霞, 蒋银, 杨丹. 酶联免疫吸附测定法与PCR仪检测在乙型肝炎诊断中的临床应用[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 310-315.
[3] 李兆明, 章颖, 刘先进. 血小板计数、红细胞分布宽度对急性戊型肝炎肝衰竭患者预后的预测价值[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 307-314.
[4] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[5] 王迎迎, 谢平. 乙型肝炎病毒感染合并肺结核患者发生肝损伤的危险因素及预测模型构建[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(04): 267-273.
[6] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[7] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[8] 范铁艳, 李君, 陈虹. 肝移植术后新发戊型病毒性肝炎的诊治经验[J]. 中华移植杂志(电子版), 2023, 17(05): 293-296.
[9] 雷雪雪, 于颖, 李虹彦. 乙型肝炎肝硬化患者肝移植等待期应用多模式预康复优化项目的临床研究[J]. 中华移植杂志(电子版), 2023, 17(03): 158-163.
[10] 陈淑钿, 梁韵, 廖媛, 王杨. 补体C3在HBV相关慢加急性肝衰竭患者预后评估中的价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 562-566.
[11] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[12] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[13] 李金璞, 饶向荣. 抗病毒药物和急性肾损伤[J]. 中华肾病研究电子杂志, 2023, 12(05): 287-290.
[14] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[15] 陈翀, 游冉冉, 王敏, 周豪杰. 单试剂HBsAg阳性、核酸检测阴性献血者的血液安全性评估[J]. 中华临床实验室管理电子杂志, 2023, 11(02): 95-98,104.
阅读次数
全文


摘要